Hendrik Schulze-Koops

51PUBLICATIONS
191CO-AUTHORS
Rheumatology and arthritisMolecular targetsHaematologyImmunogenetics (incl. genetic immunology)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (51)

|Aug 04, 2026
Therapeutic approaches for difficult-to-treat rheumatoid arthritis: a systematic literature review of current evidence.

|Jul 20, 2026
Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.

|Jun 30, 2026
The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis.

|Feb 26, 2026
Impact of the 2023/24 Influenza Vaccination on Patients with Inflammatory Rheumatic Disease in Germany: Insights from a Nationwide, Longitudinal, Self-Reported Study.

Karolina Gente, Benedikt Ditz, Eike Bormann

|Dec 25, 2025
Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials.

Vibeke Strand, Hendrik Schulze-Koops, Samar Al-Emadi

|Oct 23, 2025
Adverse events of SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease during repeated vaccination: An observational cohort study.

Liam Huppke, Christina Gebhardt, Lea Grümme

Pageof 9

Frequent Collaborators

9 joint publications

Rebecca Hasseli

6 joint publications

Pedro M Machado

6 joint publications

Gerd-Rüdiger R Burmester

6 joint publications

Christof Specker